Olympus Corp. of the Americas, a company that makes medical technology to improve people's health and safety, has launched its new SecureFlex™ Fine Needle Biopsy Device in the U.S. This device is used for taking tissue samples with ultrasound guidance to help diagnose diseases like pancreatic cancer.
The SecureFlex™ needle helps doctors collect larger tissue samples and can reach hard-to-access areas, such as parts of the pancreas. The needle comes in three sizes: 19G, 22G, and 25G.
Olympus will showcase this new device at two events: the Cedars-Sinai Endoscopy Symposium in Los Angeles (Jan. 28-31) and the Orlando Live Endoscopy 2026 event.
The technique used for this biopsy is called Endoscopic Ultrasound-guided Fine Needle Biopsy (EUS-FNB). It combines ultrasound and endoscopy to take samples from hard-to-reach lesions by using ultrasound imaging to guide the needle through the gastrointestinal tract.
At Olympus, their goal is to make people's lives healthier, safer, and better. As a global medical technology company, they work with doctors and healthcare experts to offer tools and services that help with early detection, diagnosis, and less invasive treatments, all to improve patient care.
Olympus Corporation of the Americas is a part of Olympus Corporation. It's based in Center Valley, Pennsylvania, USA, and has over 4,500 employees in North and South America.
Executive Statement
According to Christian Hagie, Vice President, GI EndoTherapy Business Unit Leader, Olympus Corporation of the Americas, gastroenterologists require precision and reliability when performing a biopsy for diagnostic accuracy. Olympus is excited to offer U.S. customers a dependable biopsy solution designed for precision sampling. The SecureFlex EUS-FNB needle offers an advanced design to help physicians perform efficient procedures by facilitating access to complex anatomical structures and obtain adequate samples for diagnostic testing, even in challenging cases.
